Impact of Letermovir Prophylaxis for Cytomegalovirus Reactivation on Post-Transplant Outcomes 100 Days before and after Allogeneic Hematopoietic Cell Transplantation

被引：0

作者：

Takenaka, Katsuto ^{[1
]}

Fuji, Shigeo ^{[2
]}

Matsukawa, Toshihiro ^{[3
]}

Uchida, Naoyuki ^{[4
]}

Kobayashi, Takeshi ^{[5
]}

Tanaka, Masatsugu ^{[6
]}

Ara, Takahide ^{[7
,8
]}

Ikegame, Kazuhiro ^{[9
]}

Ozawa, Yukiyasu ^{[10
]}

Kanda, Yoshinobu ^{[11
]}

Sawa, Masashi ^{[12
]}

Maruyama, Yumiko ^{[13
]}

Fukuda, Takahiro ^{[14
]}

Nakamae, Hirohisa ^{[15
]}

Kimura, Takafumi ^{[16
]}

Ogata, Masao ^{[17
]}

Seo, Sachiko ^{[18
]}

Atsuta, Yoshiko ^{[19
,20
]}

Matsuo, Keitaro ^{[21
]}

Nakasone, Hideki ^{[22
]}

机构：

[1] Ehime Univ, Dept Hematol Clin Immunol & Infect Dis, Grad Sch Med, Toon, Japan

[2] Osaka Int Canc Ctr Inst, Osaka, Japan

[3] Hokkaido Univ, Dept Hematol, Fac Med, Sapporo, Hokkaido, Japan

[4] Toranomon Gen Hosp, Dept Hematol, Tokyo, Japan

[5] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Div Hematol, Tokyo, Japan

[6] Kanagawa Canc Ctr, Dept Hematol, Yokohama, Kanagawa, Japan

[7] Hokkaido Univ, Dept Hematol, Fac Med, Sapporo, Hokkaido, Japan

[8] Hokkaido Univ, Grad Sch Med, Sapporo, Hokkaido, Japan

[9] Hyogo Med Univ Hosp, Dept Hematol, Nishinomiya, Hyogo, Japan

[10] Nagoya Daiichi Hosp, Japanese Red Cross Aichi Med Ctr, Nagoya, Aichi, Japan

[11] Jichi Med Univ, Dept Med, Div Hematol, Shimotsuke, Tochigi, Japan

[12] Anjo Kosei Hosp, Dept Hematol & Oncol, Anjo, Aichi, Japan

[13] Univ Tsukuba Hosp, Dept Hematol, Tsukuba, Ibaraki, Japan

[14] Natl Canc Ctr, Dept Hematopoiet Stem Cell Transplantat, Tokyo, Japan

[15] Osaka Metropolitan Univ Hosp, Dept Hematol, Osaka, Japan

[16] Japanese Red Cross Kinki Block Blood Ctr, Preparat Dept, Osaka, Japan

[17] Oita Univ Hosp, Dept Hematol, Yufu City, Japan

[18] Dokkyo Med Univ, Dept Hematol & Oncol, Mibu, Tochigi, Japan

[19] Aichi Med Univ, Sch Med, Dept Registry Sci Transplant & Cellular Therapy, Nagakute, Aichi, Japan

[20] Japanese Data Ctr Hematopoiet Cell Transplantat, Nagakute, Aichi, Japan

[21] Aichi Canc Ctr Res Inst, Div Mol Med, Nagoya, Aichi, Japan

[22] Jichi Med Univ, Div Hematol, Saitama Med Ctr, Saitama, Japan

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-180906

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5

共 50 条

[31] The impact of pre-transplant valganciclovir on early cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation
Wilhelm, Kaci
Chemaly, Roy
Saliba, Rima
Gulbis, Alison
Saunders, Ila
Cool, Rita
Ferguson, Jill
Westmoreland, Michael
Rondon, Gabriela
Kebriaei, Partow
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2014, 20 (04) : 257 - 262
[32] Letermovir vs. high-dose valacyclovir for cytomegalovirus prophylaxis following haploidentical or mismatched unrelated donor allogeneic hematopoietic cell transplantation receiving post-transplant cyclophosphamide
Freyer, Craig W.
Carulli, Alison
Gier, Shannon
Ganetsky, Alex
Timlin, Colleen
Schuster, Mindy
Babushok, Daria
Frey, Noelle, V
Gill, Saar, I
Hexner, Elizabeth O.
Luger, Selina M.
Mangan, James K.
Martin, Mary Ellen
McCurdy, Shannon R.
Perl, Alexander E.
Porter, David L.
Pratz, Keith
Smith, Jacqueline
Stadtmauer, Edward A.
Loren, Alison W.
LEUKEMIA & LYMPHOMA, 2022, 63 (08) : 1925 - 1933
[33] The Impact of Letermovir Prescribing on the Rate of Cytomegalovirus Reactivation Following Allogeneic Stem Cell Transplantation
Smith, Siobhan
Duncan, Nick
Ricketts, Laura
O'Neill, Jessica
Gautama, Brijesh
Ibrahim, Abeer
Jones, Ceri H.
Kempshall, Emma
Ingram, Wendy
Wilson, Keith
BONE MARROW TRANSPLANTATION, 2021, 56 (SUPPL 1) : 372 - 373
[34] Comparison of Cytomegalovirus Reactivation in Children After Allogeneic Hematopoietic Cell Transplantation in 2 Transplant Eras
Wen, Yu-Chuan
Wang, Yi-Lun
Chang, Tsung-Yen
Hsiao, Yi-Wen
Yang, Ying-Jie
Chen, Shih-Hsiang
Jaing, Tang-Her
TRANSPLANTATION PROCEEDINGS, 2024, 56 (08) : 1878 - 1884
[35] Human herpesvirus-6 reactivation and disease after allogeneic haematopoietic cell transplantation in the era of letermovir for cytomegalovirus prophylaxis
Kampouri, Eleftheria
Zamora, Danniel
Kiem, Erika S.
Liu, Winnie
Ibrahimi, Sarah
Blazevic, Rachel L.
Lovas, Erika A.
Kimball, Louise E.
Huang, Meei-Li
Jerome, Keith R.
Oshima, Masumi Ueda
Mielcarek, Marco
Zerr, Danielle M.
Boeckh, Michael J.
Krantz, Elizabeth M.
Hill, Joshua A.
CLINICAL MICROBIOLOGY AND INFECTION, 2023, 29 (11) : 1450.e1 - 1450.e7
[36] Letermovir for Cytomegalovirus prophylaxis in pediatric hematopoietic stem cell transplantation
Chen, Teaghan T.
David, Alexandria P.
Barthelmess, Erin K.
MacBrayne, Christine E.
PEDIATRIC BLOOD & CANCER, 2024, 70 (11)
[37] CYTOMEGALOVIRUS REACTIVATION IN PEDIATRIC PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT
Camacho-Bydume, Christine
Rodriguez-Sanchez, M. Irene
Papanicolaou, Genovefa
Prockop, Susan
Klein, Elizabeth
Cancio, Maria
PEDIATRIC BLOOD & CANCER, 2019, 66
[38] Impact of Letermovir Primary Cytomegalovirus Prophylaxis on 1-Year Mortality After Allogeneic Hematopoietic Cell Transplantation: A Retrospective Cohort Study
Su, Yiqi
Stern, Anat
Karantoni, Eleni
Nawar, Tamara
Han, Gyuri
Zavras, Phaedon
Dumke, Henry
Cho, Christina
Tamari, Roni
Shaffer, Brian
Giralt, Sergio
Jakubowski, Ann
Perales, Miguel-Angel
Papanicolaou, Genovefa
CLINICAL INFECTIOUS DISEASES, 2022, 75 (05) : 795 - 804
[39] Comment on: Letermovir for Cytomegalovirus prophylaxis in pediatric hematopoietic cell transplantation
Styczynski, Jan
PEDIATRIC BLOOD & CANCER, 2023, 70 (12)
[40] Letermovir prophylaxis reduces the risk for CMV reactivation after allogeneic stem cell transplantation
Koch, K.
Herhaus, P.
Osswald, L.
Braitsch, K.
Bassermann, F.
Verbeek, M.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 62 - 62

← 1 2 3 4 5 →